Published in Transplant Proc on March 01, 1977
STUDIES OF UREA EXCRETION. III: The Influence of Body Size on Urea Output. J Clin Invest (1928) 45.56
STUDIES OF UREA EXCRETION: VI. Comparison of the Blood Urea Clearance with Certain Other Measures of Renal Function. J Clin Invest (1930) 7.46
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Enzymatic iodination of polypeptides with 125I to high specific activity. Biochim Biophys Acta (1971) 6.67
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Factors influencing endothelial cell proliferation in vitro. J Cell Physiol (1978) 2.99
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant (2010) 2.56
Studies on antigen-binding cells. I. The origin of reactive cells. Cell Immunol (1970) 2.53
Transplantation of porcine fetal pancreas to diabetic patients. Lancet (1994) 2.52
"Spontaneous" B cell activation due to loss of normal mouse serum suppressor. Eur J Immunol (1972) 2.38
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35
Agarose gel electrophoresis. Scand J Clin Lab Invest Suppl (1972) 2.32
Phase-coupling of theta-gamma EEG rhythms during short-term memory processing. Int J Psychophysiol (2002) 2.09
Severe and common side-effects of amphotericin B lipid complex (Abelcet) Bone Marrow Transplant (1998) 2.05
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
Transcriptomic and proteomic patterns of systemic inflammation in on-pump and off-pump coronary artery bypass grafting. Circulation (2005) 1.83
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82
Polyclonal antibody secretion in human lymphocytes induced by killed staphylococcal bacteria and by lipopolysaccharide. Scand J Immunol (1977) 1.82
Sequential changes of plasma proteins after myocardial infarction. Scand J Clin Lab Invest Suppl (1972) 1.79
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Xylene-free method for histological preparation: a multicentre evaluation. Lab Invest (2001) 1.70
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol (2004) 1.66
Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant (1990) 1.65
Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining. J Immunol Methods (1993) 1.60
HLA and rheumatoid arthritis. A study of five families. Tissue Antigens (1981) 1.58
Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplant (1998) 1.58
No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant (2008) 1.56
HL-A antigens in sarcoidosis. Tissue Antigens (1973) 1.55
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant (2004) 1.55
Plaque-formation by non-immune and x-irradiated lymphoid cells on monolayers of mouse embryo cells. Nature (1965) 1.55
Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant (2003) 1.54
Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood (1998) 1.51
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother (1991) 1.50
Spleen cells from animals tolerant to a thymus-dependent antigen can be activated by lipopolysaccharide to synthesize antibodies against the tolerogen. J Exp Med (1976) 1.48
Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol (1993) 1.48
Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol (2007) 1.46
Role of polyclonal activation in specific immune responses. Relevance for findings of antibody activity in various diseases. Scand J Immunol (1980) 1.46
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 1.45
Nature of the tumor-associated determinant(s) of carcinoembryonic antigen. Proc Natl Acad Sci U S A (1975) 1.43
Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol (1994) 1.41
Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant (2003) 1.39
Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg (2004) 1.39
Transplantation of peripheral blood progenitor cells from unrelated donors. Transplantation (1998) 1.37
Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A (1989) 1.36
Antigen binding cells in tolerant animals. Nature (1970) 1.35
In vitro assay of cell-mediated immunity: the inhibition of migration of sensitized human lymphocytes by HL-A antigens. Clin Exp Immunol (1970) 1.32
Scandiatransplant: preliminary report of a kidney exchange program. Transplant Proc (1971) 1.32
Studies on antigen-binding cells. II. Relationship to antigen-sensitive cells. Cell Immunol (1970) 1.31
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother (1986) 1.31
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
B-cell mitogenic effects on human lymphocytes of rabbit anti-human beta 2-microglobulin. Scand J Immunol (1975) 1.27
Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy (2009) 1.27
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant (1998) 1.27
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis (1985) 1.25
The role of adherent cells in B and T lymphocyte activation. Immunol Rev (1978) 1.23
Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant (2008) 1.22
Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion (1997) 1.21
Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion (1998) 1.21
Drainage of thoracic duct lymph in renal transplant patients. Transplantation (1976) 1.21
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol (2006) 1.21
HLA-DR-DQ haplotypes defined by restriction fragment analysis. Correlation to serology. Hum Immunol (1987) 1.20
Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood (1992) 1.19
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood (2000) 1.19
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant (2000) 1.17
Quantitative immunochemical determination of lysoqyme (muramidase) in serum and urine. Scand J Clin Lab Invest (1971) 1.17
Complete heart block--another HLA B27 associated disease manifestation. Tissue Antigens (1983) 1.16
Changes in plasma high density lipoproteins in chronic male alcoholics during and after abuse. Scand J Clin Lab Invest (1978) 1.16
CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol (1993) 1.14
B-cell activation of peripheral blood lymphocytes from patients with chronic lymphatic leukaemia. Clin Exp Immunol (1978) 1.14
An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol (1985) 1.13
Successful outcome of segmental human pancreatic transplantation with enteric exocrine diversion after modifications in technique. Lancet (1982) 1.12
Cytotoxicity by nonimmune allogeneic lymphoid cells. Specific suppression by antibody treatment of the lymphoid cells. J Exp Med (1967) 1.12
Only one DQ-beta restriction fragment pattern of each DR specificity is associated with insulin-dependent diabetes. J Immunol (1986) 1.11
Induction of antibody synthesis in human B lymphocytes by different polyclonal B cell activators: evaluation by direct and indirect PFC assays. Immunol Rev (1979) 1.10
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood (2001) 1.10
G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant (2003) 1.09
Isolation of crystalline lactoferrin from human milk. Acta Chem Scand (1969) 1.08
Glutathione transferase in the urine: a marker for post-transplant tubular lesions. Kidney Int (1988) 1.08
Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation (1984) 1.08
High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol (2000) 1.08
Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol (1998) 1.08
The alpha chain, not the beta chain of HLA-DR antigens participates in activation of T cells in autologous mixed lymphocyte reaction. Immunogenetics (1982) 1.07
Identical-twin bone marrow transplants for leukemia. Ann Intern Med (1994) 1.07
Short communication immune mechanisms in human recipients of renal allografts. Cell Immunol (1970) 1.07
B cell differentiation factor in synovial fluid of patients with rheumatoid arthritis. Immunol Rev (1984) 1.07
Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant (1998) 1.07
HLA phenotypes and diabetic retinopathy. Diabetologia (1978) 1.06
Reduction and proteolytic degradation of immunoglobulin A from human colostrum. Acta Chem Scand (1966) 1.06
Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant (2007) 1.06
Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl (1985) 1.05
Activation of human B and T lymphocytes by protein A of Staphylococcus aureus. Eur J Immunol (1978) 1.05
Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant (1997) 1.05
HLA haplotypes in families with high frequency of multiple sclerosis. Arch Neurol (1976) 1.04